MedKoo product information:

  PF-03732010 

Description of PF-03732010:  PF-03732010 is an agent that inhibits p-cadherin (cdh3), with potential antineoplastic activity. PF-03732010 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit tumor cell invasion and proliferation in p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of solid tumors, and plays a role in cell adhesion, motility, invasion and proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer: Pfizer

1: Park J, Park E, Han SW, Im SA, Kim TY, Kim WH, Oh DY, Bang YJ. Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer. Invest New Drugs. 2011 Jul 1. [Epub ahead of print] PubMed PMID:  21720740.

2: Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes  K, Christensen JG, VanArsdale T. PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res. 2010 Nov 1;16(21):5177-88. Epub 2010 Sep 9. PubMed PMID: 20829331.